Blog
RSS FeedPosted by Michael Wonder on 24 Nov 2021
ICER to assess gene therapy for beta thalassaemia
24 November 2021 - Report will be subject of New England CEPAC meeting in June 2022; draft scoping document open ...
Posted by Michael Wonder on 17 Nov 2021
ICER publishes final evidence report and policy recommendations on mavacamten for hypertrophic cardiomyopathy
16 November 2021 - Concerns about long-term safety influenced majority of independent appraisal committee to vote that evidence is not currently ...
Posted by Michael Wonder on 16 Nov 2021
ICER identifies most significant 2020 US drug price hikes not supported by new clinical evidence
16 November 2021 - Out of 10 identified drugs that had substantial 2020 price increases net of rebates on top of ...
Posted by Michael Wonder on 11 Nov 2021
Bolstering our ability to value health technology: a few less considered issues
9 November 2021 - Proposals for a national entity to produce and assess evidence about the relative value of medical technology ...
Posted by Michael Wonder on 09 Nov 2021
ICER releases draft evidence report on tirzepatide for type 2 diabetes mellitus
9 November 2021 - Public comment period now open until 8 December 2021; requests to make oral comment during public ...
Posted by Michael Wonder on 04 Nov 2021
ICER publishes evidence report on tezepelumab for severe asthma
4 November 2021 - Tezepelumab reduces asthma exacerbations, but there is uncertainty about long-term safety as with all new biologic ...
Posted by Michael Wonder on 20 Oct 2021
ICER publishes final evidence report and policy recommendations on therapies for myasthenia gravis
20 October 2021 - Independent appraisal committee found the evidence is adequate to demonstrate that eculizumab and efgartigimod both provide a ...
Posted by Michael Wonder on 07 Oct 2021
ICER publishes evidence report on mavacamten for hypertrophic cardiomyopathy
7 October 2021 - Evidence is rated as promising but inconclusive to determine whether mavacamten provides a net health benefit for ...
Posted by Michael Wonder on 17 Sep 2021
ICER releases draft evidence report on therapies for severe asthma
16 September 2021 - Public comment period now open until 14 October 2021; requests to make oral comment during public ...
Posted by Michael Wonder on 14 Sep 2021
Branded price variation in the United States drug market, 2010 to 2019
13 September 2021 - Branded drug prices command considerable attention in the United States yet defining a drug’s price is not ...
Posted by Michael Wonder on 10 Sep 2021
ICER publishes evidence report on treatments for myasthenia gravis
10 September 2021 - While eculizumab and efgartigimod each provide important health benefits, both would need to be priced more than ...
Posted by Michael Wonder on 09 Sep 2021
Controversy over using quality adjusted life years in cost effectiveness analyses: a systematic literature review
8 September 2021 - Researchers and policy makers in the US are exploring the implementation of health technology assessment and value ...
Posted by Michael Wonder on 26 Aug 2021
ICER to assess treatments for COVID-19
26 August 2021 - Report will be subject of Midwest CEPAC meeting in April 2022; Draft Scoping Document open to public ...
Posted by Michael Wonder on 25 Aug 2021
ICER to assess novel agents to prevent chemotherapy-induced neutropenia
25 August 2021 - Report will be subject of CTAF meeting in April 2022; draft scoping document open to public comment ...
Posted by Michael Wonder on 24 Aug 2021
ICER uses observational real world evidence to update 2018 assessment on therapies for hereditary angioedema, finds therapies far less cost effective than earlier estimates
24 August 2021 - Patients initiating therapy in real world dataset had less frequent baseline attack rates than rates from clinical ...